These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 2327180)

  • 21. Augmentation of lymphokine-activated killer cell activity by lentinan.
    Tani M; Tanimura H; Yamaue H; Tsunoda T; Iwahashi M; Noguchi K; Tamai M; Hotta T; Mizobata S
    Anticancer Res; 1993; 13(5C):1773-6. PubMed ID: 8267381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
    LeFor AT; Eisenthal A; Rosenberg SA
    J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of calcitonin gene-related peptide on apoptosis of peripheral blood mononuclear cells from patients with systemic lupus erythematosus.
    Liu C; Chen X; Jin Y; Qu R; Jiang PF; Wen GM; Tang ZH
    Clin Exp Dermatol; 2007 Nov; 32(6):650-3. PubMed ID: 17725664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IL-2-activated cord blood mononuclear cells.
    Derzic S; Slone V; Sender L
    Cytotherapy; 2005; 7(5):408-16. PubMed ID: 16236630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture.
    Eisenthal A; Barbarsteyn E; Gitstein G; Lifschitz-Mercer B
    Cancer Invest; 2006 Feb; 24(1):28-34. PubMed ID: 16466989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
    Kasid A; Bell GI; Director EP
    J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mononuclear phagocytes from patients with active systemic lupus erythematosus down-regulate the specific in vitro reactivity of autologous lymphocytes to double-stranded DNA.
    Weill BJ; Renoux ML
    Clin Exp Immunol; 1988 Apr; 72(1):43-9. PubMed ID: 3293851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversible interleukin-2 response defects in systemic lupus erythematosus.
    Warrington RJ; Sauder PJ; Homik J; Ofosu-Appiah W
    Clin Exp Immunol; 1989 Aug; 77(2):163-7. PubMed ID: 2789113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The effect of interleukin-2 on peripheral lymphocytes and monocytes. III. Proliferative and cytotoxic effects in vitro in patients with systemic erythematosus and progressive polyarthritis].
    Jíra M; Strejcek J; Zavadil Z; Antosová E; Rejholec V
    Cas Lek Cesk; 1988 Dec; 127(52):1609-12. PubMed ID: 3265892
    [No Abstract]   [Full Text] [Related]  

  • 31. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
    Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA
    J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of recombinant human IL-2 in miniature swine.
    Nakajima K; Smith CV; Mixon A; Rosengard BR; Guzzetta PC; Spitzer TR; Eckhaus MA; Sachs DH
    Transplant Proc; 1991 Feb; 23(1 Pt 1):248-50. PubMed ID: 1990524
    [No Abstract]   [Full Text] [Related]  

  • 33. The effect of the alpha 2-HS-glycoprotein on the mitogen-induced lymphoblastic transformation and IL-2 production.
    Jakab L; Jakab L; Kalabay L; Pozsonyi T; Cseh K
    Acta Physiol Hung; 1991; 77(1):25-31. PubMed ID: 1950589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deficient interleukin-2-activated killer cell cytotoxicity in patients with systemic lupus erythematosus.
    Froelich CJ; Guiffaut S; Sosenko M; Muth K
    Clin Immunol Immunopathol; 1989 Jan; 50(1 Pt 1):132-45. PubMed ID: 2783399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro effects of prostaglandin E2 or indomethacin on the proliferation of lymphokine-activated killer cells and their cytotoxicity against bladder tumor cells in patients with bladder cancer.
    Wang Z; Chen Y; Zheng R; Qin D; Chen X; Wang Y; Liu G
    Prostaglandins; 1997 Nov; 54(5):769-79. PubMed ID: 9491207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aci-reductones enhance interleukin-2-induced lymphocyte cytotoxicity.
    Triozzi PL; Ailabouni J; Rinehart JJ; Witiak DT
    Int J Immunopharmacol; 1993 Jan; 15(1):47-54. PubMed ID: 8432623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody-dependent cellular cytotoxicity in systemic lupus erythematosus.
    Láng I; Fekete B; Pálóczi K; Sonkoly I; Szegedi G; Török K; Gergely P; Petrányi G
    Acta Med Acad Sci Hung; 1977; 34(4):259-65. PubMed ID: 618057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of interleukin 2 in inducing normalization of natural killer activity in systemic lupus erythematosus.
    Gaspar ML; Alvarez-Mon M; Gutiérrez C
    Clin Immunol Immunopathol; 1988 Nov; 49(2):204-14. PubMed ID: 3139345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effects of Astragalus membranaceus and Tripterygium hypoglancum on natural killer cell activity of peripheral blood mononuclear in systemic lupus erythematosus].
    Zhao XZ
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 1992 Nov; 12(11):669-71, 645. PubMed ID: 1301849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-2 restores the depressed allogeneic cell-mediated lympholysis and natural killer cell activity in patients with systemic lupus erythematosus.
    Tsokos GC; Smith PL; Christian CB; Lipnick RN; Balow JE; Djeu JY
    Clin Immunol Immunopathol; 1985 Mar; 34(3):379-86. PubMed ID: 3156017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.